Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Delivering Stem Cell Therapy from the Nose Proves Safe and Effective

By BiotechDaily International staff writers
Posted on 15 Jan 2013
Researchers have devised a simple, safe, and effective way to deliver stem cells to treat brain tumor, via the nose.

The study’s findings were published in the December 2012 issue of the journal STEM CELLS Translational Medicine. Treatment alternative for gliomas, the most common type of primary brain tumors, are very limited because of their diffuse invasive makeup and their ability to evade radiation treatments and traditional chemotherapy. Stem cells have shown great potential as a therapy, but how to deliver them optimally to the tumor site has become a challenge.

The most frequently used technique, surgical implantation, has a low survival rate for the stem cells and the procedure itself can lead to complications such as inflammation. Injecting the cells into the blood stream is another approach, but it carries an increased risk of the cells amassing in peripheral organs, which could cause side effects and also means that not enough of the stem cells are getting to the targeted tumor.

“We investigated the feasibility of intranasal administration of neural stem/progenitor cells [NSPC] as an alternative,” said lead principal investigator Nils Ole Schmidt, MD, of the University Medical Center Hamburg-Eppendorf (UMCHE; Hamburg, Germany). He and UMCHE colleague Matthias Reitz, MD, supervised the study, which also involved researchers from the University of British Columbia Hospital (Vancouver, Canada), and Chung-Ang University College of Medicine (Seoul, Korea).

The scientists assessed their notion on three different glioma cell lines in mice. The findings revealed that not only did the stem cells arrive at the targeted tumor, but that they did it rapidly and without remaining in any peripheral regions. The stem cells, Six hours after the first delivery, had enriched within the tumor area. Twenty-four hours later, the number of cells in the tumor had increased even more with up to 24% of stem cells that had been applied as nose drops.

The study also revealed two major migration routes--the olfactory nerve pathways and the small blood vessels that comprise the body’s microvasculature system--and a potential signal that attracted the cells to the malignant tumor. “It is likely that guidance signals such as chemotactic factors released by the tumor itself and the adjacent reactive brain parenchyma drew in the stem cells,” Dr. Reitz said.

“Our study provides proof-of-concept that the noninvasive intranasal passage of NSPC is a highly attractive and efficient alternative method of cell administration for stem cell-based therapies in brain tumors. This offers the possibility of multiple treatments, potentially with different therapeutic payloads during the disease course,” Dr. Schmidt added.

“The study addresses an important aspect of any stem cell treatment: identification of a safe and effective delivery method as the treatment advances toward clinical trials,” said Dr. Anthony Atala, editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine (Durham, NC, USA). “These results point to the potential of intranasal delivery as a convenient and noninvasive option for delivery.”

Related Links:
University Medical Center Hamburg-Eppendorf
University of British Columbia Hospital
Chung-Ang University College of Medicine


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.